These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 8794181

  • 1. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA.
    Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
    [No Abstract] [Full Text] [Related]

  • 2. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1993 Jan 14; 328(2):73-80. PubMed ID: 7677965
    [Abstract] [Full Text] [Related]

  • 3. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 14; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea therapy in thalassemia.
    Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, Cozma G, Tsiarta H, Pavlides N.
    Ann N Y Acad Sci; 1998 Jun 30; 850():120-8. PubMed ID: 9668534
    [Abstract] [Full Text] [Related]

  • 5. Reactivation of fetal hemoglobin in patients with beta-thalassemia.
    Olivieri NF.
    Semin Hematol; 1996 Jan 30; 33(1):24-42. PubMed ID: 8714583
    [No Abstract] [Full Text] [Related]

  • 6. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
    Musallam KM, Taher AT, Cappellini MD, Sankaran VG.
    Blood; 2013 Mar 21; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
    [Abstract] [Full Text] [Related]

  • 7. Reversing ontogeny.
    Bunn HF.
    N Engl J Med; 1993 Jan 14; 328(2):129-31. PubMed ID: 7677964
    [No Abstract] [Full Text] [Related]

  • 8. Hydroxyurea for sickle cell anemia.
    Naina HV, Harris S.
    N Engl J Med; 2008 Jul 03; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract] [Full Text] [Related]

  • 9. Pathophysiologically based drug treatment of sickle cell disease.
    Steinberg MH.
    Trends Pharmacol Sci; 2006 Apr 03; 27(4):204-10. PubMed ID: 16530854
    [Abstract] [Full Text] [Related]

  • 10. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
    Dover GJ, Charache S, Boyer SH.
    Trans Assoc Am Physicians; 1984 Apr 03; 97():140-5. PubMed ID: 6085527
    [No Abstract] [Full Text] [Related]

  • 11. DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
    Fathallah H.
    Clin Adv Hematol Oncol; 2008 Nov 03; 6(11):806-8. PubMed ID: 19194363
    [No Abstract] [Full Text] [Related]

  • 12. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
    Dover GJ.
    Ann N Y Acad Sci; 1998 Jun 30; 850():80-6. PubMed ID: 9668530
    [Abstract] [Full Text] [Related]

  • 13. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Jun 30; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 14. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A, Menzel S, Gupta R, Al-Sharida S, Farag A, Haider M, Akbulut N, Mustafa N, Thein SL.
    Am J Hematol; 2015 Jul 30; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract] [Full Text] [Related]

  • 15. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
    Italia KY, Jijina FF, Chandrakala S, Nadkarni AH, Sawant P, Ghosh K, Colah RB.
    J Clin Pharmacol; 2010 Feb 30; 50(2):231-4. PubMed ID: 19797538
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms.
    Yang YM, Pace B.
    Pediatr Pathol Mol Med; 2001 Feb 30; 20(1):87-106. PubMed ID: 12673846
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors.
    Cao H.
    Hematology; 2004 Jun 30; 9(3):223-33. PubMed ID: 15204104
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia.
    Atweh GF, Loukopoulos D.
    Semin Hematol; 2001 Oct 30; 38(4):367-73. PubMed ID: 11605172
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
    Fathallah H, Sutton M, Atweh GF.
    Ann N Y Acad Sci; 2005 Oct 30; 1054():228-37. PubMed ID: 16339670
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic stimulation of Hb F in patients with sickle cell anemia.
    Galanello R, Veith R, Papayannopoulou T, Stamatoyannopoulos G.
    Prog Clin Biol Res; 1985 Oct 30; 191():433-45. PubMed ID: 2413479
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.